US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

2.00

+0.09004.71%

Post-market: 2.010.0100+0.50%19:46 EDT

Volume:443.03K

Turnover:875.90K

Market Cap:230.53M

PE:-4.14

High:2.02

Open:1.91

Low:1.89

Close:1.91

52wk High:6.79

52wk Low:1.46

Shares:115.27M

Float Shares:64.21M

Volume Ratio:1.46

T/O Rate:0.69%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4830

EPS(LYR):-0.9225

ROE:-59.10%

ROA:-34.98%

PB:1.15

PE(LYR):-2.17

Loading ...

Overview Company News Filings

NovaBridge Biosciences Gains US FDA Fast Track Status for Gastroesophageal Cancer Therapy

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye

NovaBridge wins FDA fast track for givastomig combo in first-line HER2-negative metastatic gastric cancer

Novabridge Biosciences - Registrational Phase 3 Trial for Givastomig Expected to Begin as Early as Q4 2026

THOMSON REUTERS

Novabridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer

THOMSON REUTERS

Novabridge Biosciences - Detailed Phase 1B Data for Givastomig Expected in H2 2026

THOMSON REUTERS

NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36

Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list

Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth

Simply Wall St.

H.C. Wainwright Sticks to Its Buy Rating for NovaBridge Biosciences (NBP)

NovaBridge management to join H.C. Wainwright BioConnect Investor Conference fireside chat

Insider’s Bold Move Signals Rising Confidence in NovaBridge Biosciences

NovaBridge President, CCO Hagler acquires $577,300 common shares

Extended ceasefire only prolongs market uncertainty, gold’s medium-term prospects strengthen while silver demand slides – Heraeus

NovaBridge Biosciences’ Hagler named president, chief commercial officer, files Form 3 ownership statement

NovaBridge names Mark Hagler president and chief commercial officer

Press Release: NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value

NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs

NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/NBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":2,"timestamp":1787342400000,"preClose":1.91,"halted":0,"volume":443031,"hourTrading":{"tag":"盘后","latestPrice":2.01,"preClose":2,"latestTime":"19:46 EDT","volume":877,"amount":1748.9,"timestamp":1787356001071,"change":0.01,"changeRate":0.005,"amplitude":0.01},"delay":0,"changeRate":0.04712041884816758,"floatShares":64212900,"shares":115266053,"eps":-0.483,"marketStatus":"Market Closed","change":0.09,"latestTime":"08-21 16:00:00 EDT","open":1.91,"high":2.02,"low":1.889,"amount":875899.8435281999,"amplitude":0.068586,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.483,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.91,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.91,"latestTime":"09:15 EDT","volume":4169,"amount":7804.1324515,"timestamp":1787318100261,"change":0.04,"changeRate":0.020942,"amplitude":0.041885},"postHourTrading":{"tag":"盘后","latestPrice":2.01,"preClose":2,"latestTime":"19:46 EDT","volume":877,"amount":1748.9,"timestamp":1787356001071,"change":0.01,"changeRate":0.005,"amplitude":0.01},"volumeRatio":1.4636051748026337,"impliedVol":1.8929,"impliedVolPercentile":0.7635},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64212900,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":1.4636051748026337,"shares":115266053,"dividePrice":0,"high":2.02,"amplitude":0.068586,"preClose":1.91,"low":1.889,"week52Low":1.46,"pbRate":"1.15","week52High":6.79,"institutionHeld":0,"latestPrice":2,"eps":-0.483,"divideRate":0,"volume":443031,"delay":0,"ttmEps":-0.483,"open":1.91,"prevYearClose":3.98,"prevWeekClose":1.96,"prevMonthClose":1.6,"prevQuarterClose":1.95,"fiveDayClose":1.96,"twentyDayClose":1.77,"sixtyDayClose":1.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"Pre-MKt","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-08-21","current":-4.140787,"percent":1,"low":-20.276437,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"high":-1.87904,"avg":-8.685292,"sd":6.054305,"marketCap":220888642},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642}],"updateTime":1787513840434},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643575487","title":"NovaBridge Biosciences Gains US FDA Fast Track Status for Gastroesophageal Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575487","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575487?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:41","pubTimestamp":1781610076,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences  said Tuesday the US Food and Drug Administration granted fast track designation to its experimental therapy, givastomig, in combination with nivolumab and chemotherapy, for certain previously untreated patients with HER2-negative advanced or metastatic gastroesophageal adenocarcinoma.The company said the fast track designation is intended to accelerate the development and regulatory review of therapies that address serious conditions and unmet medical needs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4585","BK4139","BK4588","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751790","title":"BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643751790?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609654,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL6N42O0S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOYY","LU2065171311.SGD","ROBN","SG9999015978.USD","IE00BGHQDM52.EUR","BK4098","BK4141","BK4551","BK4573","LU0081259029.USD","BK4231","LU1244550221.USD","IE00BVYPNP33.GBP","QCMD","LU0079474960.USD","LU1244550577.SGD","BK4604","LU2065170008.USD","MBLY","BK4588","HOOZ","IE00BSNM7G36.USD","BK4532","BK4515","SG9999015945.SGD","BK4527","IE00BVYPNQ40.USD","HUN","LU1861559042.SGD","LU0868494617.USD","GB00BDT5M118.USD","SG9999001424.SGD","LU2065171402.SGD","LU1066051225.USD","ALVO","BK4581","BK4554","HMYY","LU1084165304.USD","BK4605","HIMS","QCOM","LU2106854487.HKD","BK4127","LU1046421795.USD","HIYY","BK4157","LU1035775433.USD","BK4512","HOOY","BK4139","BK4547","LU0061475181.USD","LU1823568750.SGD","LU1261432733.SGD","HIMY","BK4124","BK4561","HOOI","LU1244550494.USD","LU1066051498.USD","LU1069344957.HKD","HOOW","HOOX","HOOG","LU2023250504.SGD","SG9999015986.USD","BK4539","BK4575","NBP","BK4612","SG9999002224.SGD","LU1917777945.USD","HOII","BK4196","LU0054578231.USD","BK4585","LU1066051811.HKD","LU1974910355.USD","BK4080","QCMU","LU1119994496.HKD","QCML","HOOD","SG9999015952.SGD","LU0868494708.USD","LU2247934214.USD","LU1066053197.SGD","MAC","LU1861558580.USD","BK4598","BK4534","HODU","LU2065169927.USD","LU0942090050.USD","BK4579","SG9999002232.USD","HIMZ","LU1496350502.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759457","title":"NovaBridge wins FDA fast track for givastomig combo in first-line HER2-negative metastatic gastric cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759457","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759457?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:01","pubTimestamp":1781607680,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences received FDA Fast Track designation for givastomig with nivolumab and chemotherapy in first-line HER2-negative metastatic GEA.Early-stage findings showed strong anti-tumor activity with manageable tolerability, supporting further development in a biomarker-selected population.A registrational Phase 3 trial is expected to start as early as Q4 2026, setting up the next major value inflection point.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL65dnHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759675","title":"Novabridge Biosciences - Registrational Phase 3 Trial for Givastomig Expected to Begin as Early as Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759675?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575962","title":"Novabridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575962?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275918","title":"Novabridge Biosciences - Detailed Phase 1B Data for Givastomig Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275918?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640853921","title":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2640853921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640853921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:47","pubTimestamp":1780440460,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported an RSU vesting into 9,382 ordinary shares on May 30, 2026.Xu sold 3,494 ordinary shares on June 1, 2026 at USD 3.94 per share.Directly owned ordinary shares stood at 290,154 following the sale.Directly held restricted share units totaled 32,637 after the vesting transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7FngBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640393487","title":"Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list","url":"https://stock-news.laohu8.com/highlight/detail?id=2640393487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640393487?lang=en_us&edition=fundamental","pubTime":"2026-06-01 16:09","pubTimestamp":1780301388,"startTime":"0","endTime":"0","summary":"Hangzhou State Capital Investment and Operations reported multiple direct-investment portfolio companies ranked in the “2026 Future Healthcare 100” lists.Innovation devices, intelligent manufacturing Top 100: BrainCo; ChengTian Technology.Innovative drugs, biologics Top 100: Qihan Bio; Linke Pharma; Haichang Bio; Triastek; Kejun Pharma; Lingyi Bio.Health services, industry-chain services Top 100: Ailios; Heiyu Science.Other invested companies cited in the sector: Deepwise AI Lab; Yangli Pharma; Nurotron; I-Mab; Yuyan Pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou State Capital Investment and Operations Co Ltd published the original content used to generate this news brief on June 01, 2026, and is solely responsible for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5rn0qQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688769","title":"Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688769?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:17","pubTimestamp":1779880679,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbp/novabridge-biosciences/news/companies-like-novabridge-biosciences-nasdaqnbp-can-afford-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbp/novabridge-biosciences/news/companies-like-novabridge-biosciences-nasdaqnbp-can-afford-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NQmain","PSQ","QDTE","NDX","QID","TQQY","JEPQ","NBP","ONEQ","MNQmain","TQQQ","QQQA","GPIQ","BK4139","IYW","FTEC",".IXIC","QQQ","QQQY","QQQM","QLD","SQQQ","NVIW.SI","TECS","QQQE","QYLG","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638544518","title":"H.C. Wainwright Sticks to Its Buy Rating for NovaBridge Biosciences (NBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638544518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638544518?lang=en_us&edition=fundamental","pubTime":"2026-05-27 01:45","pubTimestamp":1779817523,"startTime":"0","endTime":"0","summary":"In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on NovaBridge Biosciences, with a price target of $9.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-novabridge-biosciences-nbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-novabridge-biosciences-nbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634187522","title":"NovaBridge management to join H.C. Wainwright BioConnect Investor Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2634187522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634187522?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:04","pubTimestamp":1778583868,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences management to join H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbdTtvS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","NBP","BK4112","NDAQ","LU2095319765.USD","LU0314104364.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD","LU2210149790.SGD","BK4588","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631551385","title":"Insider’s Bold Move Signals Rising Confidence in NovaBridge Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2631551385","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631551385?lang=en_us&edition=fundamental","pubTime":"2026-04-29 10:03","pubTimestamp":1777428208,"startTime":"0","endTime":"0","summary":"New insider activity at NovaBridge Biosciences ( ($NBP) ) has taken place on April 28, 2026. Mark Arnold Hagler has significantly increased his sta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insiders-bold-move-signals-rising-confidence-in-novabridge-biosciences-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insiders-bold-move-signals-rising-confidence-in-novabridge-biosciences-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631533182","title":"NovaBridge President, CCO Hagler acquires $577,300 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2631533182","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631533182?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:08","pubTimestamp":1777406903,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences President, Chief Commercial Officer Mark Arnold Hagler reported a purchase of 230,000 ordinary shares at USD 2.51 per share.Beneficial ownership stood at 230,000 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDLcgH4fC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NovaBridge President, CCO Hagler acquires $577,300 common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031303","title":"Extended ceasefire only prolongs market uncertainty, gold’s medium-term prospects strengthen while silver demand slides – Heraeus","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031303","media":"Kitco","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630031303?lang=en_us&edition=fundamental","pubTime":"2026-04-27 14:49","pubTimestamp":1777272540,"startTime":"0","endTime":"0","summary":"(Kitco News) – The ceasefire between the U.S. and Israel and Iran is beginning to turn the conflict into a prolonged one, which markets don’t seem to fully grasp, and while the bull market for gold sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"kitco_highlight","url":"https://www.kitco.com/news/article/2026-04-27/extended-ceasefire-only-prolongs-market-uncertainty-golds-medium-term","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.kitco.com/news/article/2026-04-27/extended-ceasefire-only-prolongs-market-uncertainty-golds-medium-term","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"kitco_highlight","symbols":["KSLV","GDX","IAU","SIL","OUNZ","SIVR","SLV","AAAU","CEF","AGQ","DBC","GBUG","GDXD","IAUI","GDXU","XME","JDST","PICK","DUST","JNUG","GLDM","BEGS","BK4504","GOLY","PHYS","SLVP","BK4207","GDXJ","RING","ZSL","NBP","SGOL","GLL","UGL","BTGD","USG","BK4588","FGDL","DZZ","GLTR","SLVR","SILJ","BAR","DGP","BK4547","GDXY","IAUM","PSLV","1OZmain","DULL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629802034","title":"NovaBridge Biosciences’ Hagler named president, chief commercial officer, files Form 3 ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629802034","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629802034?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:09","pubTimestamp":1776888599,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences filed an initial Form 3 for Mark Arnold Hagler, president and chief commercial officer, dated April 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL62M1ZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629704864","title":"NovaBridge names Mark Hagler president and chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629704864","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629704864?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:08","pubTimestamp":1776856090,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences appointed Mark Hagler as president and chief commercial officer.Hagler previously built commercial strategy for Abraxane in new indications.He also led global launch of a core Afinitor indication.Role adds commercial leadership as NovaBridge advances givastomig toward registrational pivotal studies in first-line gastric cancer.Appointment also supports pre-commercial readiness for VIS-101, a dual VEGF-A x ANG-2 inhibitor program in wet AMD.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL7bgG9l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","NBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","NDAQ","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629104060","title":"Press Release: NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2629104060","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629104060?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"-- Seasoned Biopharma leader bringing deep commercial experience to shape. and inform corporate strategy, clinical trial design and business. givastomig, a potential first-in-class Claudin 18.2 x 4-1BB bispecific. potential best-in-class, dual VEGF-A x ANG-2 inhibitor for wet AMD. \"Welcoming Mark adds meaningful commercial and operational leadership experience to NovaBridge. This year, NovaBridge has demonstrated strong momentum, with compelling clinical data from our two mid-stage, potential best-in-class/first-in-class programs, givastomig and VIS-101. As we progress towards pivotal studies, Mark's perspective will be instrumental in defining our path forward to maximize the value of our pipeline for shareholders and patients,\" said Fu Wei, Executive Chairman of the Board of NovaBridge.\"Joining NovaBridge at this pivotal time is incredibly exciting. I look forward to partnering with my colleagues as we advance givastomig and VIS-101 to pivotal studies. The pipeline is supported by co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","NBP","BK4139","R","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494826","title":"NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494826","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494826?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:56","pubTimestamp":1775645760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 06:56 ET (10:56 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625961863","title":"NovaBridge Biosciences Highlights 2025 Results and Advances Late-Stage Oncology and Ophthalmology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625961863","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625961863?lang=en_us&edition=fundamental","pubTime":"2026-04-08 05:21","pubTimestamp":1775596905,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences ( ($NBP) ) has issued an update. On April 7, 2026, NovaBridge Biosciences reported its full-year 2025 results, underscoring ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novabridge-biosciences-highlights-2025-results-and-advances-late-stage-oncology-and-ophthalmology-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novabridge-biosciences-highlights-2025-results-and-advances-late-stage-oncology-and-ophthalmology-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NBP","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625696988","title":"NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2625696988","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625696988?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595030,"startTime":"0","endTime":"0","summary":"NovaBridge posted a net loss of USD 88.3 million for fiscal year 2025, widening from USD 22.2 million a year earlier.Revenue was unchanged at no revenue, versus USD 632,000 in 2023.Operating loss widened to USD 94.3 million as research and development expenses more than doubled to USD 62.9 million.Cash and cash equivalents totaled USD 210.6 million at year-end, with net cash used in operating activities of USD 20.6 million.NovaBridge forecast cash, cash equivalents and short-term investments of USD 210.8 million will fund operations into Q4 2028, while highlighting givastomig Phase 2 first-patient enrollment and plans to start a registrational Phase 3 trial as early as Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL2vRNKr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74,"code":"91000000","status":"200"}]}}